Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2012 Oct;59(4):753-5. doi: 10.1002/pbc.23391. Epub 2012 Feb 7.

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Author information

1
Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA. smithm@ctep.nci.nih.gov

Abstract

Arsenic trioxide was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5 mg/kg daily × 5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC(50) value of 0.9 µM, with Ewing sarcoma cell lines having IC(50) values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed.

PMID:
22315235
PMCID:
PMC3612422
DOI:
10.1002/pbc.23391
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center